Related references
Note: Only part of the references are listed.Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice
Ying Yu et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials - The cross trial safety analysis
Scott D. Solomon et al.
CIRCULATION (2008)
Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association
Elliott M. Antman et al.
CIRCULATION (2007)
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon et al.
LANCET (2006)
Celecoxib for the prevention of sporadic colorectal adenomas
Monica M. Bertagnolli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
T Grosser et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population
Luis A. Garcia Rodriguez et al.
BMC MEDICINE (2005)
Role of prostacyclin in the cardiovascular response to thromboxane A2
Y Cheng et al.
SCIENCE (2002)
Risk of cardiovascular events associated with selective COX-2 inhibitors
D Mukherjee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
